Business Wire

IQM’s State of Quantum 2025: Quantum Industry Must Solve Talent Shortage and Software Platforms, Not Just Qubits

Share

The report predicts that quantum computing market will hit over $22 billion globally by 2032 as commercial deployments accelerate. Highlights how AI, high-performance computing (HPC), and quantum technology are converging to drive the next wave of growth. This is the third edition of the state of quantum report by IQM Quantum Computers.

IQM Quantum Computers in collaboration with analyst firm Omdia (LON:INF), today unveiled the third edition of its State of Quantum Report, revealing that the quantum industry must address talent shortages and software development kits (SDK) gaps in order to scale beyond just qubit count.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250610552224/en/

IQM State of Quantum 2025 Report

As quantum computing shifts from theoretical promise to practical integration, the report projects that the global quantum computing market will reach over $22 billion by 2032 as commercial deployments accelerate.

The findings also show that 75% of respondents believe that defining the right applications is the most critical factor for adoption. As Dr. Jan Goetz, Co-CEO and Co-founder of IQM, noted in his foreword, “Quantum’s promise is clear, but fulfilling it requires orchestrated progress across the hardware and software stack—transforming these powerful machines from niche tools into drivers of real-world outcomes.”

The report also argues that progress hinges on synchronising hardware industrialisation with software platform maturity. Today, software development kit fragmentation hampers portability and slows adoption in multi-vendor settings.

HPC, Quantum, and AI Integration

The report also highlights how high-performance computing (HPC), quantum computing, and AI are converging to drive the next wave of growth. According to industry experts, investors, and users across Europe, North America, Asia, and Oceania interviewed, HPC provides the robust infrastructure and orchestration needed to integrate quantum systems into real-world environments, ensuring that quantum and classical resources work in harmony.

This synergy promises to accelerate adoption, amplify returns for early adopters, and transform quantum computing from a niche capability into a trusted part of the broader scientific and industrial toolbox.

“Our interviewees identified three major challenges – one is getting to the level of reliability where quantum computers can be considered industrial products rather than crafted laboratory devices, another is improving the software layer to provide the sort of developer experience we see in the high-level frameworks used for AI, and a third is helping users identify opportunities to benefit from quantum computer and set up their experiments. Interestingly, the interviewees are expecting multiple quantum technologies to co-exist, with a degree of specialisation between them,” said Alexander Harrowell, Principal Analyst, Advanced Computing at Omdia.

Key Findings and Market Trends

  • Sector Readiness: 57% of survey respondents placed drug-discovery and molecular-modelling workloads as their top quantum priority list, ahead of finance and chemicals.
  • Funding: After a dip in 2023, venture funding surged again in 2024, with 58% of cumulative quantum venture funding still flowing to North American firms, with average deal sizes ($38M) triple those in Europe ($12M).
  • Challenges Ahead: Talentshortages in quantum and growth-stage funding outside the US are the two biggest systemic risks to the industry’s continued growth.

In addition, the report also calls for three critical priorities to turn these insights into tangible outcomes:

  • Better Abstraction Layers: Bridging the gap between the physics of qubits and the practical problems that matter to businesses.
  • Unified Orchestration and Scheduling: Enabling quantum and classical HPC resources to operate seamlessly together.
  • Cross-Disciplinary Collaboration: Fostering teams that blend quantum expertise, domain knowledge, and software development—creating a new generation of problem-solvers.

Download the full report here: State of Quantum 2025 Report.

About IQM Quantum Computers:

IQM is a global leader in superconducting quantum computers. IQM provides both on-premises full-stack quantum computers and a cloud platform to access its computers. IQM customers include the leading high-performance computing centres, research labs, universities and enterprises which have full access to IQM's software and hardware. IQM has over 300 employees with headquarters in Finland and a global presence in France, Germany, Italy, Japan, Poland, Spain, Singapore, South Korea and the United States.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250610552224/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet13.6.2025 00:45:00 CEST | Press release

POD1UM-303/InterAACT 2 is the first and largest global Phase 3 trial evaluating a PD-1 inhibitor in combination with chemotherapy for the treatment of patients with advanced SCAC not previously treated with systemic chemotherapy The trial met its primary endpoint; treatment with retifanlimab in combination with platinum-based chemotherapy (carboplatin-paclitaxel) resulted in clinically meaningful improvements in progression-free survival and overall survival In May 2025, the U.S. Food and Drug Administration (FDA) approved Zynyz® (retifanlimab-dlwr) in combination with carboplatin and paclitaxel and as a single agent for the treatment of advanced SCAC; submissions to other global regulatory agencies are also under review Incyte (Nasdaq:INCY) today announced that primary results from the Phase 3 POD1UM-303/InterAACT 2 trial of retifanlimab (Zynyz®), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), in combination with carboplatin and paclitaxel (platinum-base

Güntner Drives Group-Wide Innovation in 2024 Sustainability Report12.6.2025 21:30:00 CEST | Press release

Progress in natural refrigerants, water efficiency and circular economy underscores Güntner’s global impact Güntner, a global leader in refrigeration and heat exchange technology, today announced its featured role in the newly released 2024 A-HEAT Sustainability Report. The report outlines significant progress toward ambitious environmental goals—fueled by Güntner’s commitment to measurable, innovation-led sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612897493/en/ Güntner advances global sustainability goals with progress in natural refrigerants, water savings, and circular economy efforts. Working toward its 2030 sustainability targets, Güntner delivered significant achievements across key areas including natural refrigeration integration, water and energy efficiency and the development of circular economy solutions. These efforts reflect Güntner’s ongoing mission to make sustainability not just a goal,

Windsurf Launches First GPU Cluster in Germany, Expanding Secure Enterprise AI in Europe12.6.2025 20:45:00 CEST | Press release

Windsurf launches a GPU cluster in Germany, delivering 50% faster performance and secure access to European enterprises. Data residency ensures enterprise repositories stay within the EU, meeting stringent security requirements. Windsurf already supports 100+ European enterprise customers, highlighting strong demand for AI-powered development tools across EMEA. Windsurf, a leader in AI-powered software development, today announced its first GPU cluster in Germany, as product demand surges and the company expands performance capacity across the EU. With over 100 local enterprise customers already using Windsurf products, the new cluster marks the company’s first major international step in building scalable infrastructure for the European market. Located in Frankfurt, home to some of the world’s strictest data security laws, the cluster was a natural choice for Windsurf’s first deployment. This cluster was specifically designed to meet the unique security and performance requirements of

Xsolla Partners With Defold to Enable Seamless In-game Purchases for Web Developers12.6.2025 19:00:00 CEST | Press release

New SDK Integration Simplifies Monetization for Defold Developers Publishing on CrazyGames Ahead of Global Game Jam Xsolla, a leading global video game commerce company, announces a new strategic partnership with Defold, the cross-platform game engine trusted by professionals and indie developers worldwide. This collaboration introduces a seamless integration between Xsolla and Defold-built web games on CrazyGames, enabling developers to easily monetize their titles just in time for the CrazyGames x Defold Game Jam running June 13–15. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250612569206/en/ (Graphic: Xsolla) To address the complexity of in-game monetization, Xsolla and Defold have developed a new SDK that allows Defold developers to implement in-game purchasing functionality without the complex manual API setup required. With Xsolla’s sponsorship and support, this integration removes friction from the monetization jou

Pioneering Cancer Plasticity Atlas will Help Predict Response to Cancer Therapies12.6.2025 17:00:00 CEST | Press release

The Wellcome Sanger Institute, Parse Biosciences, and the Computational Health Center at Helmholtz Munich today announced a collaboration to build the foundation of a single cell atlas, focused on understanding and elucidating cancer plasticity in response to therapies. The collaboration will catalyze an ambitious future phase to develop a cancer plasticity atlas encompassing hundreds of millions of cells. Utilizing novel organoid perturbation and Artificial Intelligence (AI) platforms, the aim is to create a comprehensive dataset to fuel foundational drug discovery models and cancer research. Dr. Mathew Garnett, Group Leader at the Sanger Institute, and Prof. Fabian Theis, Director of the Computational Health Center at Helmholtz Munich and Associate Faculty at the Sanger Institute, will be the principal investigators in the collaboration. Garnett’s research team has generated novel 3D organoid cultures that serve as highly scalable and functional cancer models with the ability to capt

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye